Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
General Internal Medicine
•
Hematology
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
Will the treatment for CLL improve or worsen her IgM levels?
Related Questions
In patients with AML who achieve a CR with HMA/Ven, what is the optimal dose and schedule for venetoclax for further cycles?
What factors should be considered when deciding whether to omit radiation in pediatric/AYA patients receiving N+AVD, particularly regarding long-term outcomes and second malignancy risks?
In patients with post-PV myelofibrosis who are ineligible for allogeneic stem cell transplant, how do you approach symptomatic splenomegaly refractory to splenic radiation and ruxolitinib?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
How do you approach c-KIT mutated, core binding factor (CBF) AML?
For a patient with TP53+ CLL who has been receiving first line ibrutinib for over 7 years with a complete hematologic response but detectable minimal residual disease, would you consider switching now to a novel BTKi such as acalabrutinib or zanubrutinib given better PFS data?
In treatment naive CLL without del(17p)/TP53, will the recent interim analysis of fixed duration acalabrutinib plus venetoclax +/- obinutuzumab vs chemoimmunotherapy in the AMPLIFY trial change your practice?
Does treating CLL reduce the risk of non-melanoma skin cancers?
Can AMPLIFY data be extrapolated to use of other BTKi's in combination with venetoclax or would you only ever use acalabrutinib/venetoclax in first line?